What is HC Wainwright’s Estimate for SGMO FY2024 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMOFree Report) – HC Wainwright decreased their FY2024 EPS estimates for shares of Sangamo Therapeutics in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.49) for the year, down from their previous estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.

A number of other equities analysts have also recently issued reports on SGMO. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Wells Fargo & Company dropped their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Jefferies Financial Group reduced their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Barclays increased their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Finally, Truist Financial reduced their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Sangamo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $5.17.

View Our Latest Analysis on SGMO

Sangamo Therapeutics Trading Up 8.8 %

Shares of NASDAQ SGMO opened at $1.23 on Wednesday. The company has a market cap of $256.64 million, a price-to-earnings ratio of -1.64 and a beta of 1.29. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The stock has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.33.

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.07. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter last year, the company posted ($0.34) EPS.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the period. Marshall Wace LLP lifted its stake in Sangamo Therapeutics by 56.3% in the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $89,000. Finally, Vontobel Holding Ltd. lifted its position in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Featured Stories

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.